Invex Reports $4.5M Cash, Board Changes, and New Alzheimer’s Data

Promising Research Collaboration Progress

Invex Therapeutics has provided an encouraging update on its ongoing research collaboration with Tessara Therapeutics, focusing on the repurposing of Exenatide for neurological conditions linked to raised intracranial pressure and neurodegenerative diseases such as Alzheimer’s. The latest analysis using Tessara’s ADBrain™ model reveals that Exenatide significantly reduces markers of neuronal cell stress and inflammation, including a roughly 40% decrease in neurofilament light chain levels, a biomarker associated with early Alzheimer’s progression.

Additionally, Exenatide demonstrated reductions in pro-inflammatory cytokines IL-6 and IL-8, which are key players in neuroinflammation, a hallmark of Alzheimer’s and other neurodegenerative disorders. While a 35% decrease in amyloid-beta burden was noted at higher doses, this finding requires further investigation due to experimental normalization factors. Notably, Exenatide did not affect phosphorylated Tau levels or insulin-dependent glucose uptake under the tested conditions, but signs of enhanced neural network complexity suggest potential benefits for neuronal health.

Corporate Restructuring and Governance Updates

The quarter also saw significant changes in Invex’s leadership. The resignations of two directors and the CFO in November prompted the cancellation of a scheduled shareholder meeting. Subsequently, the company appointed two new non-executive directors with extensive experience in corporate governance and healthcare industries, alongside new joint company secretaries. These changes have led to the deferral of the Annual General Meeting to February 2026, allowing shareholders to consider resolutions related to the new board composition.

Financial Position and Outlook

Invex closed the quarter with $4.5 million in cash and cash equivalents, down from $5.8 million a year earlier. Operating cash outflows increased to $0.43 million, driven primarily by higher administration and corporate costs linked to director terminations and meeting-related expenses. Research and development expenditure remained modest at $40,000 for the quarter, reflecting ongoing patent-related activities. The company continues to engage with Tessara to leverage the collaboration for intellectual property enhancement and shareholder value creation.

While the company did not provide explicit guidance on future capital raising or operational cash flow expectations, the current cash runway suggests a cautious but stable financial footing as Invex advances its clinical and corporate objectives.